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ABSTRACT
Glioblastoma (GBM) cells are characterized by high phagocytosis, lipogenesis,
exocytosis activities, low autophagy capacity and high lysosomal demand are
necessary for survival and invasion. The lysosome stands at the cross roads of lipid
biosynthesis, transporting, sorting between exogenous and endogenous cholesterol.
We hypothesized that three already approved drugs, the autophagy inducer, sirolimus
(rapamycin, Rapa), the autophagy inhibitor, chloroquine (CQ), and DNA alkylating
chemotherapy, temozolomide (TMZ) could synergize against GBM. This repurposed
triple therapy combination induced GBM apoptosis in vitro and inhibited GBM
xenograft growth in vivo. Cytotoxicity is caused by induction of lysosomal membrane
permeabilization and release of hydrolases, and may be rescued by cholesterol
supplementation. Triple treatment inhibits lysosomal function, prevents cholesterol
extraction from low density lipoprotein (LDL), and causes clumping of lysosome
associated membrane protein-1 (LAMP-1) and lipid droplets (LD) accumulation. Cotreatment of the cell lines with inhibitor of caspases and cathepsin B only partially
reverse of cytotoxicities, while N-acetyl cysteine (NAC) can be more effective. A
combination of reactive oxygen species (ROS) generation from cholesterol depletion
are the early event of underling mechanism. Cholesterol repletion abolished the ROS
production and reversed the cytotoxicity from QRT treatment. The shortage of free
cholesterol destabilizes lysosomal membranes converting aborted autophagy to
apoptosis through either direct mitochondria damage or cathepsin B release. This
promising anti-GBM triple therapy combination severely decreases mitochondrial
function, induces lysosome-dependent apoptotic cell death, and is now poised for
further clinical testing and validation.
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INTRODUCTION

lysosomal exocytosis for clearance of ER oxidative stress
[16]. We hypothesized that cholesterol trafficking between
the plasma membrane and intracellular compartments is also
a required cellular process that could also be disrupted by the
paradoxical combination of autophagy inducers (rapamycin,
Rapa) and inhibitors (Chloroquine, CQ). Synergistic effects
of this paradoxical combining had reported work in many
tumors such as melanoma, bladder cancer, colon cancer,
hepatoma, sarcoma and glioma [17–23]. In general, the
double combination may not be lethal unless elevated ER
stress is also present. Therefore, we proposed and started
testing a new “triple combination” therapeutic strategy
against a variety of cancers by combining the autophagy
inducer/inhibitor regimen with chemo- or radiotherapy
to induce ER stress. We have reported clinical safety and
promising efficacy for this triple combination strategy in
a variety of cancer patients including GBM patients, who
received standard of care TMZ plus RT (that induce ER
stress) with CQ and Rapa [24, 25].
The stress from TMZ treatment combined with
mTOR inhibition with Rapa treatment increases autophagy
demand, but CQ inhibits lysosome degradation and the
aborted autophagy increased the mitochondria burden.
CQ plus Rapa treatment decreases the glycolytic and
oxygen consumption rates, and inhibits the conversion of
cholesterol ester to free cholesterol and lipolysis from LD
resulting in cholesterol depletion destabilizes lysosomes
and causing cathepsin release. LD accumulation is a sign
of impaired mitochondria function [9]. The shortage of
fatty acid for β-oxidation resulted in energy crisis and
further potentiates the mitochondria burden and oxidation
damage and converts tumor cells to apoptosis.

GBM is an aggressive malignancy with high mortality,
and relative resistance to radiation and other treatments
[1, 2]. Current treatments include maximal surgery followed
by adjuvant radiation (RT) and chemotherapy (CT) with
TMZ [3]. The addition of bevacizumab to standard RTTMZ therapy did not improve overall survival. Pre-clinical
data suggest that this failure may be due to tumor metabolic
adaptation toward anaerobic metabolism, and increased
tumor cell invasiveness after anti-angiogenic treatment
[4, 5]. These represent examples of adaptive stress-response
by the tumor and therefore therapies that induce and amplify
tumor stress response, such as autophagy, unfolded protein
response (UPR) and cancer metabolism, represent potential
therapeutic strategies.
GBM is characterized by exaggerated lipogenesis,
enhanced LDL cholesterol uptake, high phagocytosis and
micro-vesicle exocytosis activities, and depends very
much on cholesterol homeostasis for constant membrane
changes. The majority of cholesterol is found at the plasma
membrane, enriched as raft micro-domain, while the
endoplasmic reticulum (ER), mitochondria and lysosomes
contain minimal amount of cholesterol. The lysosome is on
the end point of endocytic, phagocytic and autophagocytic
pathway and responsible for their cellular trafficking and
play the key role in maintain cholesterol homeostasis.
Because of blood brain barrier, GBM cells constantly
require cholesterol from tumor microenvironment (TME),
its high lysosomal demand may be an “Achilles’ heel”,
an exploitable vulnerability of GBM [6, 7]. Recently,
Villa et al. also showed that GBM cells are dependent on
cholesterol for survival, and succumb to Liver X receptor
(LXR) agonist-induced cholesterol depletion by decreased
influx and increased efflux of cholesterol [8]. GBM cells
can convert excessive cholesterol to cholesterol ester
for storage in LD, which were mobilized to fuel fatty
acid oxidation to sustain cell viability during nutrient
deprivation stress [9]. The suppression of LD formation
or the de novo cholesterol synthesis all had been reported
to suppress GBM growth [10, 11]. We try to disturb the
Achilles’ heel with autophagy modulation.
Compared to lower grade gliomas, GBMs express
lower intrinsic autophagy activity, whereas higher expression
of autophagy genes, LC3 and Beclin1 correlates with better
survival [12]. High grade glioma has insufficient autophagy
due to promoter hyper-methylation and downregulation of
the autophagy inducer ULK2, resulting in tumor growth
[13]. Lysosomes are primarily involved in the degradation,
recycling and secretory pathways for nutrient homeostasis
[14]. All of the inter-connections between membrane and
intracellular organelles require cholesterol homeostasis.
Intracellular cholesterol trafficking is very important for
normal ER and lysosome functions [15]. Lower tumor
autophagy activity is compensated with higher tumor
phagocytic activity to obtain nutrition from TME and higher
www.impactjournals.com/oncotarget

RESULTS
CQ, Rapa and TMZ combination treatment
synergistically increase apoptotic cell death,
inhibits cell proliferation in GBM cell lines
We investigated the effect of CQ (Q), Rapa
(R) and TMZ (T) combination treatment on cellular
apoptosis and viability in 4 GBM cells lines. As shown
in Figure 1A, induction of apoptotic cell death is most
significant with the presence of CQ in all combinations
(Q, QR, QT and QRT), slightly in RT treatment, but
not with R, and T treatments. QRT treatment resulted in
the highest level of apoptotic cell death in all GBM cell
lines. In apoptotic cell death, a clear difference emerged
in the pattern of cell death across the GBM cell lines,
dividing the cell lines into two groups. Group I cells,
GBM8401 and M059K displayed less sensitivity to
TMZ treatment, QR treatment was pretty toxic to them
and were not induced more apoptotic cell death after
QRT treatment (Figure 1A). Group II cells, U87MG and
Hs683 showed more sensitive to TMZ treatment. QRT
treatment significantly increased apoptosis comparison
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with QR and QT treatment. Expression of PARP and
cleavage caspase-3 were showed in QR/QRT treatment
of Type-I GBM cell lines and T/QT treatment of Type-II
GBM cell lines (Figure 1B). Hypermethylation of the O6methylguanine-DNA- methyltransferase (MGMT) gene
has been shown to be associated with better response to
TMZ. However, the MGMT promoter methylation status
in these GBM cell lines were not associated with TMZ
sensitivity (Supplementary Figure 1A). We, therefore,
chose GBM8401 and U87MG as representative of these
two types for further studies. The QRT combination
significantly inhibited cell proliferation especially on
U87MG cells compared with GBM8401 cells (Figure 1C).
Results of dose-dependent experiments were present
in supplementary results (Supplementary Figure 1B).
Pre-treatment with caspase 3 inhibitor z-VAD-FMK
(10 uM treatment for 1 h) can only partially reverse the
cytotoxicity in QT treated U87MG (Figure 1D) but not
others. Consequently, QRT synergism were caspase-3
independent in GBM8401 and U87MG cell lines.
Both cell lines had basal LC3II and p62 expression.
Accumulation of LC3II and p62 universally increased
with addition of CQ, suggesting that both cell lines
are moderately sensitive to autophagy inhibition
(Figure 2A). In GBM8401 and U87MG, QR and QRT
treatment decreased p-Akt activity more than with
CQ alone or QT combination (Figure 2B). Rapamycin
indeed inhibit p-p70S6k expression in both cell lines
(Figure 2C). Interestingly, CHOP expression was only
moderately increased after TMZ treatment with or without
combination therapies, suggesting that ER stress does not
significantly contribute to GBM cell death (Figure 2C
and 2D). Rapa increased autophagy and decreased CHOP
in both GBM lines, but GRP78 expression was only
observed in U87MG cells after Rapa treatment, suggested
a GRP78-induced autophagy process.

with all combinations except TMZ alone (Figure 3D,
left panel). QRT combination resulted in most severe
OCR impairment, with almost complete elimination
of mitochondrial function. In an ECAR assay, similar
decreases in glycolytic function were observed with CQ,
Rapa, RT, QT, with the most significant depression observed
with the QRT combination (Figure 3D right panel). These
results indicated that QRT treatment induced by oxidative
stress on both cells while GBM8401 was more vulnerable
to mitochondria induced metabolic catastrophe.

CQ, Rapa and TMZ combination destabilizes
lysosomes and abrogates lipid droplets
breakdown
Autophagy inhibition-mediated cellular apoptosis
was recently reported to correlate with lysosomal cell
death [27]. CQ is known to induce apoptosis by lysosomal
membrane permeabilization, cathepsin release, and
activation of BH3 interacting-domain death agonist
(BID) and caspases [28, 29]. mTORC1 inhibitors such
as Rapa decrease cholesterol biosynthesis and cause
rapid lysosome cell death [23]. We investigated whether
multiple autophagy modulations change lysosomal
function. Figure 4A show abundant clumping and swelling
of lysosomes with accumulation of LAMP-1 after Q, QR,
QT and QRT treatment. The increased cathepsin B release
from lysosomal swelling was suggested. Accordingly, we
treated cathepsin inhibitor to observe whether cathepsin
B dependent cell death played a major role. GBM8401
and U87MG were pretreated with cathepsin inhibitor for
1 h before treating them with Q, R, T and combination for
24 h. As shown in Figure 4B, in U87MG cells pretreated
with cathepsin inhibitor, cell viability was significantly
increase in Q, QR, QT and QRT treatment. However,
GBM8401 cells were partially recovered cell viability in
only Q treatment. These finding indicated that U87MG
cells is more vulnerable to lysosome cell death, while as
previously described, the GBM8401 deceased mainly by
mitochondria cell death mechanism.
When free cholesterol increases, cholesteryl esters
(CE) are formed and sequestered into LDs [30]. The
breakdown of LDs is attributed to the actions of cytosolic
hydrolytic enzymes or lipases. Recently, several studies
have demonstrated an association between the lysosomal
degradative pathway of autophagy (lipophagy) and
the breakdown of intracellular LDs stores as survival
mechanism [9, 31]. It was reported glioma cells
accumulate LDs under hypoxic conditions, and this is
directly correlated with the degree of malignancy and
tumor growth [32]. To determine the change in LDs from
baseline to post-treatment, GBM cells were visualized
with fluorescent lipid dye BODIPY 493/503. In Figure 4C,
LDs observed in GBM8401 cells slightly decreased after
Rapa or RT treatment compared to untreated controls,
suggesting that Rapa-induced lipophagy processes lead to

CQ, Rapa and TMZ combination treatment
induced oxidative stress and mitochondrial
damage through energy crisis
To investigate whether ROS induction plays a
major role in cell death after treatment with QRT. We
found treatment with Q, R alone or QT, QR or QRT
markedly increased ROS generation except T (Figure 3A).
Importantly, 20 mM NAC provided moderate to complete
protection against Q, QR, QT, and QRT treatment in both
GBM8401 and U87MG (Figure 3B), which indicated
that ROS generation played early and imperial role in
QR toxicities. Cells cultured with Q alone or QR, QRT
treatments all showed signiﬁcant loss of MMP (Figure 3C),
Rapa alone increased ROS generation but did not lead
to loss of MMP. GBM cells are characterized by high
glycolytic activity and mitochondrial dysfunction [26].
Metabolic changes were investigated with the GBM8401
cell line. As shown in Figure 3D, the OCR was decreased
www.impactjournals.com/oncotarget
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Figure 1: Effect of CQ (Q), Rapa (R) and TMZ (T) in different combination treatment on apoptosis and proliferation
in 4 GBM cell lines. All GBM cell lines were cultured as following treatment to assay apoptotic cells (GBM8401 Q 40/R 12.5/T 400 μM

24 h, M059K Q90/R 20/T 400 μM 24 h, U87MG Q 40/R 10/T 400 μM 48 h, Hs683 Q 15/R 20/T 400 48 h. (A) The population of annexin
V+ apoptotic cells was evaluated by flow cytometry using annexin V-FITC/PI staining in GBM8401 cells, M059K, U87MG and Hs683
cells after CQ, Rapa and TMZ treatment. (B) The expression of cleaved PARP and cleavage caspase-3 in GBM8401 M059K, U87MG
and Hs683 cells were analyzed by western blotting. (C) Cell proliferation in GBM8401 cells and U87MG cells after CQ, Rapa and TMZ
treatment was assessed by MTS assay. The Y-axis represents the proliferation rate, calculated as the ratio to control untreated cells. The
graphs shown represent the mean ± SE of at least three different experiments. (D) All GBM cell lines were treated CQ, Rapa, and TMZ
in different combination following 1 h caspase-3 inhibitor (z-VAD-FMK) pretreatment and then assessed for cell viability. Statistical
significance of CQ or Rapa or TMZ or combinations vs DMSO is indicated (*). Statistical significance of CQ or Rapa or combinations vs
TMZ alone is indicated (#). Statistical significance of QRT vs QR is indicated ($). Statistical significance: *P < 0.05, **P < 0.01; #P < 0.05,
##
P < 0.01, $P < 0.05.
www.impactjournals.com/oncotarget
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the breakdown of LDs. On the contrary, CQ contributed
to marked LDs accumulation from aborted lipophagy, and
TMZ resulted in modest LD accumulation - possibly a
resistance mechanism to hydrophobic drug [33].

(Figure 5C), rescued tumor cells viability (Figure 5D), and
the LDLR overexpression was not observed (Figure 5E).
LXR was not activated after CQ treatment (Figure 5E).
Previous results showed cell death in Q, QR, QT and QRT
treatment from ROS production (Figure 3B), while the
additional free cholesterol significantly decreased ROS
in in GBM8401 after Q, QR, QT, and QRT treatment
(Figure 5F). Similar result was observed in U87MG (data
not show). The results indicated that cell death of QRT
treatment closely related to cholesterol depletion and ROS
production. Cell membrane associated NADPH oxidase
activation is suspected [34, 35].

QRT treatment disturbs lipid droplet utilization
and cholesterol homoeostasis
We observed a marked increase in GBM expression
of low-density lipoprotein receptor (LDLR) in response to
the free cholesterol deficit after Q, QR, or QRT treatments
(Figure 5A). CQ inhibits the conversion of endocytosed
LDL to free cholesterol, and limited the lipophagy process
from LD. The majority of the available free cholesterol is
likely required for active cell membrane repair, to maintain
cell membrane integrity because of increased exocytosis
after triple combination treatment. The absence of ATPbinding cassette subfamiliy A membrane 1 (ABCA1),
a cellular cholesterol efflux transport, overexpression
after QRT triple combination treatment suggests that
there was no associated efflux of cholesterol through
this transporter (Figure 5A). We used filipin to visualize
cellular cholesterol in three-drug treatment. The results
show that decrease of membrane cholesterol in Q, QR,
QT and QRT treatment in both cell lines and cholesterol
treatment rescues partial membrane cholesterol in QRT
treatment (Figure 5B). The data showed that Q, T, QT
and QRT treatments result in increased exosome release,
suggesting that free cholesterol efflux might occur through
this pathway (Supplementary Figure 2). Interestingly,
addition of free cholesterol decrease lysosome swelling

The triple combination treatment effectively
treats GBM orthotropic xenografts
To further evaluate the efﬁcacy of QRT triple
treatment, NOD/SCID mice bearing intracranial
GBM8401 xenografts were treated. After 7 days
implantation GBM8401, intra-peritoneal injections of
TMZ alone, QR or QRT were performed from day 8 to day
15. Tumor progression was evaluated with IVIS imaging
over time as Figure 6A mentioned. A representative
photo image was presented in Figure 6A. Tumor cells
rapidly proliferate in untreated controls. Inhibition of
tumor cell growth is observed QRT treatment, and there
was significantly decrease tumor growth in QRT triple
treatment (Figure 6B). QRT treatment was prolonged
survival time comparison with other treatments
(Figure 6C). We sacrificed mice on day 15 based on
IACUC recommendations, loss of 25–30% of initial body

Figure 2: Autophagy, ER stress, and p-AKT change after CQ (Q), Rapa (R) and TMZ (T) in different combination
treatment. GBM8401 cells and U87MG cells were treated with CQ, Rapa and TMZ in different combinations, harvested at 24 hours and
immunoblotted for LC3-I, LC3-II and (A) p62, (B) p-AKT, (C) p-mTOR and p-S6K, (D) GRP78 and CHOP.
www.impactjournals.com/oncotarget
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Figure 3: The metabolic change after CQ (Q), Rapa (R) and TMZ (T) in different combination treatment. Cells were

treated CQ (90 or 40 μM), Rapa (12.5 or 10 μM) and TMZ (400 μM) for 24 h or 48 h. (A) ROS generation in GBM8410 and U87MG
were detected by BD Accuri™ C6 flow cytometer. Date were processed and analyzed with BD Accuri™ C6 software. GBM8401 and
U87MG cells were treated with or without 20 mM NAC. (B) Apoptosis was assessed for analysis. (C) Loss of mitochondria membrane
potential (MMP) was assessed via JC-1 staining and flow cytometry in GBM8401 and U87MG cells. The percentage of cells with low JC-1
fluorescence is shown. (D) Mitochondrial respiration and glycolytic capacity in GBM8401 Left panel: evaluation of OXPHOS capacity of
GBM8401 cells were plated at 1 × 105/well and cultured with each conditions for 2 h. Metabolic responses were evaluated after sequential
injection of the following metabolic toxins: oligomycin, FCCP, antimycin A/rotenone. Right panel: evaluation of the glycolytic capacity of
GBM8401 cultured with each conditions for 2 h. Metabolic responses were evaluated after sequential injection of the following metabolic
toxins: Glucose, oligomycin and 2-DG. Statistical significance of CQ or Rapa or TMZ or combinations vs DMSO is indicated (*). Statistical
significance of CQ or Rapa or combinations vs TMZ alone is indicated (#). Statistical significance of CQ or Rapa or TMZ or combinations
vs QRT is indicated ($). Statistical significance: *P < 0.05, **P < 0.01; #P < 0.05, ##P < 0.01, $P < 0.05.
www.impactjournals.com/oncotarget
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Figure 4: Lysosomal swelling and lipid droplets (LDs) accumulation after CQ (Q), Rapa (R) and TMZ (T) in different
combination treatment. (A) Immunostain with LAMP1 (a lysosome marker, green) and cathepsin B (red), quantified using Image J.
(B) GBM cell lines were preincubated with cathepsin inhibitor (5 μM) for 1 h before the addition of CQ, Rapa and TMZ. Histograms show
quantification of cell viability at day 1 (GBM8401) and day 2 (U87MG). (C) The change of LDs in U87MG and GBM8401 after CQ, Rapa
and TMZ combination for 24 hrs. LDs was staining by BODIPY 493/503 (green) and Hoechst 33342 (nuclear, blue). Histograms were
showed quantification of accumulation LDs by BODIPY 493/503 staining using flow cytometry. Statistical significance of CQ or Rapa or
TMZ or combinations vs DMSO is indicated (*). Statistical significance: *P < 0.05, **P < 0.01. Scale bar: 10 μm.
www.impactjournals.com/oncotarget
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Figure 5: Changes of cholesterol homeostasis under CQ (Q), Rapa (R) and TMZ (T) in different combination treatment.

(A) The expression of ABCA1, LDLR after different drug combinations for GBM 8401 cells and U87MG cells. (B) Cholesterol stain assay.
GBM8401 cells and U87MG cells were treated, fixed and stained with filipin to visualize cholesterol (green). High-magnification imaging
reveals that addition of free cholesterol (10 μg/mL) regains partial cell membrane under QRT treatment (whit arrow line display rich
cholesterol cell membrane; yellow arrow line display lacking cholesterol cell membrane). (C) Salvage treatment with free cholesterol and
stained for LAMP-1 (green). Representative images are shown alongside the quantification of lysosome swelling. (D) The added of free
cholesterol with different drug combinations could recover cell survival. (E) Decreased LDLR expression and increase ABCA1 expression
was noted, but the expression of LXR were not change. (F) ROS production was decreased after free cholesterol in Q, QR, QT, QRT
treatments in GBM8401 cells. Statistical significance is indicated (*). Statistical significance: *P < 0.05, **P < 0.01. Scale bars represent
10 μm.
www.impactjournals.com/oncotarget
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weight should be considered as death with euthanasia
administered according to institutional guidelines.

Malignant glioma has a high lipid anabolism
phenotype, enabling rapid cell proliferation [36–38].
Lipids, such as phospholipids, fatty acids, cholesterol,
triglycerides and cholesterol esters, and sphingolipids,
are important components of cells including the
caveolin membrane system [15]. Most brain cholesterol
is synthesized de novo in normal astrocytes, because
cholesterol in the bloodstream cannot be transported
across the blood brain barrier. GBM cells rely on uptake
of exogenous cholesterol from neighboring cells [8].
Increased cholesterol esterification and storage in LD,
in addition to increased LDL uptake are beneficial for
GBM [10]. Cellular cholesterol levels are controlled
by biosynthesis, cellular LDL uptake through LDL
receptors, phagocytosis and efflux from cells. Lipid
breakdown leads to release of free fatty acids that sustain
β-oxidation in the mitochondria. As shown in Figure 2A
through 4C, we observed an autophagy activation as
evident by suppression of p70S6K phosphorylation
with increased ROS production and a decreased LD
after Rapa treatment. CQ markedly increased LC3B-II

DISCUSSION
This study suggests that GBM is susceptible to the
induction of cholesterol depletion related to the lysosome
dysfunction. High cholesterol turnover is essential for
the survival of GBM cells under stress. In comparison to
mTOR inhibitor (Rapa) treatment alone, the combined
Rapa and lysosome inhibitor (CQ) with or without TMZ
therapy significantly increased apoptotic cell death
through mitochondria damage before cathepsin released
from lysosome in one type of GBM cells (GBM8401),
while the addition of TMZ decidedly increased apoptotic
cell death through cathepsin induced cell death in other
type of cells (U87G). We observed that triplet combination
(QRT) treatment is synergistic in all type of GBM cells
through depleted membrane cholesterol content along with
ROS formation and the cytotoxicity can be reversed by
external added cholesterol or NAC antioxidant.

Figure 6: Decreased tumor growth with in vivo treatment of GBM xenograft model monitored by bioluminescence
imaging. (A) The treatment schedule of GBM xenograft. GBM8401-luc cells (2 × 105) were injected stereotactically implanted into a

single defined left hemisphere location (6 weeks old, n > 4) and the bioluminescence signal was monitored by the in vivo imaging system
at the indicated days after inoculation. Seven days after tumor implanted received no treatment (control), treatment with TMZ (T, 50 mg/kg
i.p.), CQ (50 mg/kg i.p.) + Rapa (5 mg/kg i.p.) (QR) and QRT. Tumor cells spread rapidly in the untreated control mice. When the
intracranial brain tumors were treated with TMZ alone or QR, in both cases are similar patterns of untreated control. Tumor treatment by
QRT significant slowed the growth of the tumors by day 4 after implantation. (B) Mice of QRT treatment significantly inhibit tumor growth
compared with control, TMZ, and QR treatment. (C) QRT treatment was prolonged survival time. Statistical significance: Control vs QRT
(*), T vs QRT (#), QR vs QRT ($).
www.impactjournals.com/oncotarget
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conversion, p62 accumulation, lysosome clumping and
LD accumulation, which indicated of lysosome blockage.
Rapa treatment mimicked a state of nutritional starvation,
the simultaneous combined autophagy inducer and
inhibitor as QR treatment resulted in marked lysosomal
swelling and LD accumulation. Because cells depended
on LD fueled fatty acids for survival during nutrient
deprivation [9]. Lippincott-Schwartz et al. showed that
fatty acids are released from LDs by lipolysis and taken
up by fused LDs with mitochondria to support oxidative
respiration [39]. However, does fatty acid move from
LD due to cytoplasmic lipase-mediated lipolysis instead
of lipophagy, and how fatty acid trafficking after QR or
QRT treatment causes mitochondria change are interesting
issues for further study [39, 40].
In GBM cells, endolysosomes are required for
digesting extracellular lipoproteins after endocytosis,
and autophagy-mediated LD degradation also required
lysosomes for lipid mobilization. The high dependence of
GBM cells on lysosomes for lipid metabolism, coupled
with their limited autophagy capacity makes GBM cells
more vulnerable to CQ treatment-related cholesterol
deficit. Maintaining cellular free cholesterol levels is
essential for cell membrane maintenance, viable tumor
cell morphology and lysosome function. CQ blocks
cholesterol extraction from LDL contained in endosomes
and from lipid droplets by inhibiting lysosomal function.
CQ has long been known to increase rapid retrograde
LDL exocytosis and delay the hydrolysis of cholesterol
esters [39, 41]. Higher cholesterol efflux in GBM
cells through increased exocytosis instead of ABCA1
transporter are evident from exosome release after QT
treatment. Since de novo cholesterol synthesis is also
depressed with addition of Rapa-mediated SREBP
down-regulation, adequate cholesterol reserves are not
available to tumor cells. Triple QRT treatment results in
accumulation of cholesterol esters in lipid droplets and
failure of cholesterol mobilization upon ester hydrolysis,
which significantly reduces availability of free cholesterol
in tumor cells. Cellular cholesterol content directly
influences lysosomal stability, and the increased lysosomal
membrane permeability results in cathepsin release and
increases apoptosis. The production of ROS is closely
associated with cholesterol levels. NADPH oxidase is one
of the main ROS-generating enzymes present in lipid rafts
and both cholesterol content [34]. As shown in Figure 5,
cholesterol repletion abolished the ROS production and
reversed the cytotoxicity from QRT treatment.
The Warburg effect of utilizing aerobic glycolysis as
the primary supplier of ATP is found in GBM and many
cancers. However, oxidative phosphorylation (OXPHOS)
function is very important in GBM cells. A prior study
showed that glioma stem cells are less glycolytic and use
mitochondria for glucose oxidation in vivo [42–44]. Recent
studies of orthotropic GBM xenografts demonstrated that
GBM uses both glycolysis and mitochondrial oxidation for
www.impactjournals.com/oncotarget

glucose catabolism. As shown in Figure 3D, the Rapa and CQ
double combination has dual inhibitory action on OCR and
ECAR, while the mitochondria function was most severely
impaired. The decreased ATP supply further increases
cellular dependence on autophagy functions. Simultaneous
targeted disruption of multiple important cellular metabolism
pathways may synergize to result in ‘synthetic lethality’.
A recent phase II GBM clinical trial failed to show
benefit after addition of everolimus, a Rapa analogue, to
the standard TMZ regimen [45]. Activation of autophagy
alone seems to be insufficient to reverse GBM therapeutic
resistance. Our proposed approach of adding the
autophagy inhibitor CQ appears to be more promising. A
small randomized trial demonstrated the survival benefit of
adding CQ to a combination of radiotherapy and lomustine
in newly diagnosed GBM patients [46]. Rapa and CQ
has been reported to own the ability to penetrate bloodbrain barrier [47, 48]. The present study demonstrates
that cholesterol depletion may be a potential therapeutic
mechanism of CQ that overcomes limitations in caspasedependent apoptotic cell death. Therefore, this study
suggests that triple therapy of Rapa, CQ and standard
TMZ-RT treatment would be a promising therapeutic
strategy to test in clinical trials for GBM patients.

MATERIALS AND METHODS
Cell culture
GBM8401 cells, kindly provided by Professor
Hsin-Ell Wang (Department of Biomedical Imaging and
Radiological Sciences, National Yang-Ming University,
Taiwan). U87MG cells, M059K cells, and Hs683 cells
were obtained from the American Type Culture Collection
(ATCC, Manassas, VA). U87MG were cultured in MEM
with 1 mM Na pyruvate, 10% FBS and antibiotics (100 U/
ml penicillin and 100 μg/ml streptomycin). GBM8401 were
cultured in RPMI with 10% FBS and antibiotics (100 U/
ml penicillin and 100 μg/ml streptomycin). M059K were
cultured in MEM with 10% FBS, 0.1 mM NEAA, 1 mM
sodium pyruvate. Hs683 were cultured in DMEM/F12K
with 10% FBS, 0.05 mM MEAA, 0.5 mM sodium pyruvate.
Cells were grown in a 5% CO2 incubator at 37°C.

Cell proliferation assay
Cell cultures was performed by seeding at a density
of 1.0 × 105 cells/well in 96-well round-bottom plates
(Falcon, UK) containing 200 µL of medium. Various doses
of chemotherapeutic drugs and CQ, in combination with
Rapa (at different molar ratios) were added after tumor cells
reached 1 × 106 density. Treated tumor cells were maintained
for two days at 37°C in humidified 5% CO2. The rate of cell
proliferation was measured using an MTS assay (CellTiter
96 aqueous one-solution cell proliferation assay; Promega,
WI, USA). 40 µL of CellTiter 96 aqueous one-solution
6892
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were added to each well. After 4 h of incubation, the UV
absorbance of the solution was measured at a wavelength
of 490 nm. All MTS assays were performed in triplicate.

instructions. Briefly, 1 × 106 cells were washed, resuspended
in 500 μL of JC-1 working solution, then incubated at 37°C
for 15 min. Following staining, cells were washed twice
and resuspended in 500 μL of assay buffer. Cells were
immediately analyzed using a BD FACSCalibur flow
cytometer. Live cells were gated and analyzed.

Apoptosis assay
Apoptosis was assayed using an Annexin V Apoptosis
Kit (BD Pharmingen, CA, USA) according to manufacturer
instructions. Briefly, tumor cells were washed three times
with PBS, then immediately analyzed for apoptosis using
Annexin V/PI (propidium iodide) staining. Washed cells were
supplemented with 1% BSA, then directly stained with 10 µL
of PI and 2.5 µL Annexin V-FITC after adding 222.5 µL of
binding buffer. Immediately following a 10 min incubation
period in the dark on ice, the cells were analyzed by flow
cytometry. The percentage of positive cells was determined
by using a BD Accuri™ C6 and BD Accuri™ C6 software
(Becton Dickinson, Mountain View, CA, USA).

Measurement of ROS production
Intracellular ROS was detected by 2′,7′-dichloro
fluorescein diacetate (DCFDA, Sigma). Cells were washed
with PBS and incubated with DCFDA (0.25 µM) for 10
min at 37°C. The florescence intensity was detected using
BD Accuri™ C6 and BD Accuri™ C6 software. Untreated
cells were used for normalization.

Evaluation of oxygen consumption and
extracellular acidification rate of metabolic
parameters

Western blot analysis

Metabolic responses of GBM8401 cells were
evaluated with an Extracellular Flux Analyzer (XFe24;
Seahorse Biosciences, North Billerica, MA) according
to manufacturer instructions. The Extracellular Flux
Analyzer measures oxygen consumption and extracellular
acidification rates (ECAR) of a defined number of cells in
a small culture media volume in real time, and monitors
cellular responses to drug treatment. In brief, 5 × 104 cells
were seeded in XFe24-well plates and incubated overnight
at 37°C in a 5% CO2 humidified atmosphere, followed
by treatment with indicated drug concentrations for 2 hr.
After 2 hr, mitochondrial respiration was measured by
oxygen consumption rate (OCR), and glycolysis was
evaluated by ECAR after injecting the following inhibitors
of mitochondrial respiration: oligomycin (inhibitor of ATP
synthase, 1 uM), FCCP (uncoupling factor), Antimycin
A/Rotenone (inhibitor of mitochondrial complex I of
the ETC), and 2-deoxyglucose (2-DG; inhibitor of
hexokinase). Basal OCR and ECAR were measured, as
well as the changes in oxygen consumption caused by
adding the above metabolic inhibitors.

For protein analysis, cells were lysed for 5 min at
room temperature in a buffer composed of 150 mM NaCl,
50 mM Tris (pH 8.0), 5 mM EDTA, 1% (v/v) Nonidet
p-40, 1 mM phenylmethylsulfonyl fluoride, 20 µg/mL
aprotinin, and 25 µg/mL leupeptin (Sigma). The total
protein concentration of lysates was measured using the
Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA).
Cell lysate (100 µg) was electrophoresed on a 12%
polyacrylamide gel and the proteins were transferred to
an Immobilon-P PVDF membrane (Millipore, Bedford,
MA, USA), which was then blocked for 2 h at room
temperature in PBS containing 0.05% Tween 20 and 10%
nonfat milk. The membrane was then incubated with
antibodies against β-actin (Sigma, 1:10000), GAPDH
(Sigma, 1:10000), LC3 (Novus Biologicals Inc., Littleton,
CO, 1:10000), SQSTM1/p62 (MBL international,
1:1000), PARP (Cell Signaling Technologies, 1:1000),
phospho-mTOR, phospho-Akt (Ser 473) (Cell Signaling
Technologies, 1:1000), phospho-p70S6K (Cell Signaling
Technologies, 1:1000), ABCA1 (Abcam, 1:1000), LDLR
(Abcam, 1:5000), SREBP1 (BD, 1:1000), SREBP2 (BD,
1:1000), CHOP (Cell Signaling Technologies, 1:1000) and
GRP78 (Cell Signaling Technologies, 1:1000) overnight
at 4°C in PBS containing 0.05% Tween 20 and 5% nonfat
milk, followed by incubation for 1 h at room temperature
with horseradish peroxidase-conjugated secondary
antibodies (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) in the same buffer. Blots were developed
using a chemiluminescent detection system (ECL; GE Life
Science, Buckinghamshire, UK).

Immunofluorescence
U87MG and GBM8401 cells were fixed with 4%
paraformaldehyde for 15 min at room temperature and
the samples were twice-washed with PBS. Samples
were then incubated for 10 mins with PBS containing
0.25% Triton X 100 followed by PBS rinse three times
for 5 mins. After incubating the cells with 1% BSA in
PBST for 30 min, they were probed with a mixture of
two primary antibodies, Cathepsin B (ab58802, Abcam,
1:500), and LAMP1 (#9091, cell signaling, 1:500) in
1% BSA in PBST for 1 hr at room temperature. Images
were captured using a Zeiss LSM800 with AirScan laser
confocal microscope.

Determination of mitochondrial membrane
potential (MMP)
MMP was measured using a BD MitoScreen kit
(JC-1, BD Biosciences) according to the manufacturer’s
www.impactjournals.com/oncotarget
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Lipid and cholesterol staining

10 min later using the Xenogen IVIS imaging system
(Xenogen, Palo Alto, CA, USA), with a 1-min acquisition
time in small-bin mode. Luciferase activity was quantiﬁed
within a region of interest that encompassed the head of
the mouse using Living Image Software (Xenogen, Palo
Alto, CA, USA).

U87MG and GBM8401 cells were fixed with ice-cold
methanol for 10 min and washed thrice with PBS, followed
by incubation with 1 ml of 1.5 mg glycine/ml PBS for 10
min at room temperature. Free cholesterol in cells was
stained with 1 ml of Fillipin (Sigma-Aldrich, St. Louis, MO,
USA) working solution (0.05 mg/ml in PBS/10% FBS) for
2 h at room temperature. For LD staining, fixed monolayers
with 4% paraformaldehyde were incubated with 10 μg/
ml BODIPY 493/503 (Molecular Probes, Eugene, OR,
USA) for 30 min at room temperature. Slides were washed,
stained with Hoechest (Cell signaling, Technology, Beverly,
MA, USA) and visualized using fluorescent microscopy
(Zeiss LSM800 with AirScan laser confocal microscope).

Statistical analysis
All statistical analyses were performed using Prism
4 (GraphPad Software, Inc., La Jolla California USA,
www.graphpad.com). The experimental and control
groups were compared using an unpaired two-tailed
Student’s t test. Statistical analysis was performed at the
P < 0.05 (denoted as *).

Intracranial glioma orthotropic xenograft model

CONFLICTS OF INTEREST

Human brain malignant glioma cells from the
GBM8401 cell line were transformed with the luciferase
gene (GBM8401-luc). All procedures were performed
according to the guidelines approved by the Animal Care
and Use Committee of the National Yang-Ming University.
Male 6- to 8-week-old NOD/SCID mice were anesthetized
via intraperitoneal administration of pentobarbital at
40 mg/kg body weight. Their heads were shaved above
the nape of the neck, scrubbed with Betadine/alcohol,
and immobilized in a Cunningham Mouse/Neonatal
Rat Adaptor stereotactic apparatus (Stoelting, Wood
Dale, IL, USA). A 5-mm skin incision was made at the
sagittal suture, then a burr hole was created, and 2 × 105
GBM8401-lu cells in 2 μl of culture medium were injected
stereotactically implanted into a single defined left
hemisphere location (0.14 mm anterior and 2.0 mm lateral
to the bregma) of each mouse brain at a 3.5 mm depth.
The skull burr hole was then sealed with bone wax and the
wound was ﬂushed with iodinated alcohol. Biophotonic
imaging was used to confirm tumor engraftment.

MM has served as a consultant to Varian, Agenus,
Insys, and Remedy and serves on the data safety
monitoring committee for Monteris. JSK is a consultant
to Kiyatec, Inc. KHC has stock ownership and leadership
position in JohnPro Biotech Inc.
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